NASDAQ · Biotechnology

Janux Therapeutics, Inc. (JANX) Stock

$18.39 -0.59% NASDAQ: JANX Healthcare

Valuation

MetricValue
Price$18.39
Market Cap$1.12B
P/E Ratio-10.32
P/B Ratio1.15
P/S Ratio32.39
EPS (TTM)$-1.83
52-Week High$35.34
52-Week Low$12.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-10.79%
ROA-10.18%
ROCE-15.15%
Gross Margin-1580.00%
Operating Margin-1580.00%
Net Margin-321.81%
Debt/Equity0.02
Current Ratio39.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$9.0M$8.0M$11.0M$10.0M
Operating Profit$-33.0M$-67.0M$-73.0M$-99.0M$-158.0M
Net Profit$-33.0M$-63.0M$-58.0M$-69.0M$-114.0M
EPS$-0.79$-1.52$-1.32$-1.28$-1.83
Op Margin-905.4%-779.0%-902.9%-933.6%-1576.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$380.0M$364.0M$380.0M$1.1B$1.0B
Total Liabilities$13.0M$43.0M$36.0M$39.0M$51.0M
Cash$36.0M$51.0M$19.0M$431.0M$52.0M
Borrowings$0$25.0M$25.0M$23.0M$22.0M

Latest News

Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? Simply Wall St. · Jul 9, 2026 VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? Insider Monkey · Jun 30, 2026 Akari Therapeutics Highlights 1st ASCO Abstract Acceptance IPO-Edge.com · May 28, 2026 VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC Exec Edge · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$-43.0M$-51.0M$-44.0M$-82.0M
Investing Cash Flow$-342.0M$52.0M$-43.0M$-258.0M$-302.0M
Financing Cash Flow$2.0M$0$3.0M$15.0M$0
Net Cash Flow$29.0M$16.0M$-32.0M$411.0M$-378.0M
Free Cash Flow$-18.0M$-49.0M$-52.0M$-44.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.45
EV / EBITDA-10.14
FCF Yield-5.28%
Quick Ratio16.35
Interest Coverage0.00
Return 1Y-40.59%
Return 3Y15.25%
Return 5Y-41.10%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CGEMCullinan Therapeutics, Inc. $15.53 +0.45% -4.60 $954.44M 0.00%
CLDXCelldex Therapeutics, Inc. $29.89 +2.01% -7.26 $1.99B 0.00%
CMPXCompass Therapeutics, Inc. $0.99 +0.98% -2.06 $178.83M 0.00%
CTMXCytomX Therapeutics, Inc. $2.57 +4.05% -5.69 $559.50M 0.00%
IMNMImmunome, Inc. $19.55 +1.24% -8.23 $1.87B 0.00%

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is led by CEO David Alan Campbell, employs 91 people, headquartered in US, publicly traded since 2021.

Janux Therapeutics, Inc. (JANX) stock trades at $18.39 with a market capitalization of $1.12B. The stock is valued at a price-to-earnings (P/E) ratio of -10.32, price-to-book of 1.15, price-to-sales of 32.39. Over the past 52 weeks the stock has ranged between $12.12 and $35.34, and currently trades 48.0% below its 52-week high.

On profitability, Janux Therapeutics, Inc. generates a return on equity (ROE) of -10.79%, return on capital employed of -15.15%, an operating margin of -1580.00%, a net profit margin of -321.81%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides